Thomas Baumert News Today

Lixudebart (ALE.F02) is a first-in-class monoclonal antibody in clinical development for multi-organ fibrosis Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing

BASEL, Switzerland, April 29, 2024--Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective immediately. Alberto joined Alentis in 2021 as Head of Oncology.

Velji brings more than 20 years of experience in biotech financial servicesBASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today announced that Rizwan Velji has been appointe...

BASEL, Switzerland--(BUSINESS WIRE)--#CLDN1--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong a...

BASEL, Switzerland, August 29, 2023--Late-Breaking Oral Presentation on ALE.F02 as Potential Treatment for Pulmonary Fibrosis

The trial confirms ALE.F02's good safety profile, exposure and target biological activity Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing breakthrough treatments

Proceeds will fund:- Clinical programs ALE.F02 and ALE.C04 – two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors- The platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodiesBASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”)...

Alentis Therapeutics ("Alentis"), the Claudin-1 (CLDN1) company, is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Today, Alentis announced $105 million in Series C financing. The funding...

/PRNewswire/ -- Novo Holdings A/S, a leading international life sciences investor, today announced it has participated in a new investment in the US$105...

Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1